入院时黏弹性止血检测参数可预测脑出血长期不良结局
该单中心队列研究纳入2013至2020年收治的44例自发性脑出血患者,排除既往抗凝药物使用或常规凝血检测异常者,入院时行旋转血栓弹力检测(ROTEM)。在校正脑出血严重程度和血红蛋白浓度后,凝血形成时间每延长1秒与6个月改良Rankin量表≥4分独立相关(校正OR 1.04,95%CI 1.00-1.09,P=0.04),最大血凝块强度每增加1毫米与不良结局独立相关(校正OR 0.84,95%CI 0.71-0.99,P=0.03)。作者认为需进一步研究以明确这些发现的普遍性和机制,并评估VHA指导的治疗是否应纳入脑出血管理。
要点
- 44例自发性脑出血患者中64%在6个月时改良Rankin量表≥4分,中位脑出血体积23 mL,平均年龄64岁,57%为女性。
- 凝血形成时间每延长1秒,6个月不良结局的校正OR为1.04(95%CI 1.00-1.09,P=0.04)。
- 最大血凝块强度每增加1毫米,6个月不良结局的校正OR为0.84(95%CI 0.71-0.99,P=0.03)。
- 以上关联在校正脑出血严重程度和血红蛋白浓度后仍存在,且不归因于抗凝药物使用。
- 作者认为需进一步研究以明确这些VHA发现的普遍性和机制,并评估VHA指导的治疗是否应纳入脑出血管理。
适用人群与场景
- 2013至2020年纳入单中心队列研究的自发性脑出血患者,入院时接受ROTEM黏弹性止血检测。
- 排除既往使用抗凝药物者,以及常规凝血检测提示凝血异常者。
诊断标准与关键阈值
- 不良长期结局定义为6个月时改良Rankin量表评分≥4分。
- 主要ROTEM暴露变量为凝血动力学指标和血凝块强度指标。
研究设计与关键结果
- 单中心队列研究,共分析44例患者,平均年龄64岁,57%为女性,中位脑出血体积23 mL,64%在6个月时改良Rankin量表≥4分。
- 在校正脑出血严重程度和血红蛋白浓度的多因素回归模型中,凝血形成时间每延长1秒与不良长期结局相关(校正OR 1.04,95%CI 1.00-1.09,P=0.04)。
- 在校正脑出血严重程度和血红蛋白浓度的多因素回归模型中,最大血凝块强度每增加1毫米与不良长期结局相关(校正OR 0.84,95%CI 0.71-0.99,P=0.03)。
证据类型、等级与局限
- 证据类型:单中心队列研究。
- 作者结论:入院时VHA ROTEM检测示凝血动力学减慢延长和血凝块强度减弱(不归因于抗凝药物使用)与脑出血后不良长期结局相关。
- 局限:作者指出需进一步研究以明确这些VHA发现的普遍性和潜在机制,并评估VHA指导的治疗是否应纳入脑出血管理。
对床旁实践的改变
- 作者认为,入院时ROTEM示凝血动力学减慢延长和血凝块强度减弱与脑出血后不良长期结局相关;需进一步研究明确这些发现的普遍性和机制,并评估VHA指导的治疗是否应纳入脑出血管理。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Viscoelastic hemostatic assays (VHAs) provide more comprehensive assessments of coagulation compared with conventional coagulation assays. Although VHAs have enabled guided hemorrhage control therapies, improving clinical outcomes in life-threatening hemorrhage, the role of VHAs in intracerebral hemorrhage (ICH) is unclear. If VHAs can identify coagulation abnormalities relevant for ICH outcomes, this would support the need to investigate the role of VHAs in ICH treatment paradigms. Thus, we investigated whether VHA assessments of coagulation relate to long-term ICH outcomes.
METHODS: Patients with spontaneous ICH enrolled into a single-center cohort study receiving admission Rotational Thromboelastometry (ROTEM) VHA testing between 2013 and 2020 were assessed. Patients with previous anticoagulant use or coagulopathy on conventional coagulation assays were excluded. Primary ROTEM exposure variables were coagulation kinetics and clot strength assessments. Poor long-term outcome was defined as modified Rankin Scale ≥ 4 at 6 months. Logistic regression analyses assessed associations of ROTEM parameters with clinical outcomes after adjusting for ICH severity and hemoglobin concentration.
RESULTS: Of 44 patients analyzed, the mean age was 64 years, 57% were female, and the median ICH volume was 23 mL. Poor 6-month outcome was seen in 64% of patients. In our multivariable regression models, slower, prolonged coagulation kinetics (adjusted odds ratio for every second increase in clot formation time 1.04, 95% confidence interval 1.00-1.09, p = 0.04) and weaker clot strength (adjusted odds ratio for every millimeter increase of maximum clot firmness 0.84, 95% confidence interval 0.71-0.99, p = 0.03) were separately associated with poor long-term outcomes.
CONCLUSIONS: Slower, prolonged coagulation kinetics and weaker clot strength on admission VHA ROTEM testing, not attributable to anticoagulant use, were associated with poor long-term outcomes after ICH. Further work is needed to clarify the generalizability and the underlying mechanisms of these VHA findings to assess whether VHA-guided treatments should be incorporated into ICH care.
参考来源
- Sieh L, Peasley E, Mao E, et al. Admission Viscoelastic Hemostatic Assay Parameters Predict Poor Long-Term Intracerebral Hemorrhage Outcomes. Neurocrit Care. 2024. PMID: 38955933. doi:10.1007/s12028-024-02051-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。